MedTrace Logo

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

NCT04674969 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2026-05-15

No results posted yet for this study

Summary

The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.

Conditions

  • Peripheral Vascular Diseases

Interventions

DEVICE

Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.

Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-29
Primary Completion
2028-01-31
Completion
2028-01-31
FDA Device
Yes

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • China
  • France
  • Germany
  • Poland
  • Spain
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04674969 on ClinicalTrials.gov